Trial reportEuropean journal of heart failure2023
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Trial report in European journal of heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Pooled it
- GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Pooled it
- Association of weight loss with cardiovascular or all-cause mortality in patients with heart failure: A meta-analysis.International journal of obesity (2005) · 2024Pooled it
- Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.Internal and emergency medicine · 2024Pooled it
- Beyond biomarkers: designer natriuretic peptides and cGMP centered therapies for cardiorenal and cardiometabolic protection in chronic heart failure.Internal and emergency medicine · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors in Underweight Patients with Heart Failure: A Case Series.Journal of clinical medicine · 2026Article
- Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?European heart journal · 2026Review
- SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.ESC heart failure · 2025Review
- Obesity and heart failure: exploring the cardiometabolic axis.Cardiovascular research · 2025Review
- Obesity and its management in primary care setting.Journal of diabetes and its complications · 2025Review
- Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Heart Failure and Low Body Mass Index.Circulation reports · 2025Article
- Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database.Pharmacological reports : PR · 2025Article
- Effect of empagliflozin on weight in patients with prediabetes and diabetes.Scientific reports · 2025Article
- The Impact of Obesity on Cardiovascular Diseases: Heart Failure.Methodist DeBakey cardiovascular journal · 2025Review
- Review
- Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.Basic research in cardiology · 2024Article
- Safety and Efficacy of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: Multicentre Retrospective Study on Echocardiographic Parameters and Biomarkers of Heart Congestion.Journal of clinical medicine · 2024Article
- Prognostic influence of weight loss on overweight/obese young heart failure patients.Saudi medical journal · 2024Article
- The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?Journal of personalized medicine · 2024Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 12 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsBaseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes. METHODS AND
resultsWe categorized patients according to their baseline BMI: <20 kg/m
conclusionThe benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.